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Abstract
Background: Currently, there are no strict post-biopsy guidelines for managing stereotactic biopsy-proven benign lesions mani-
festing as microcalcifications on mammography without an accompanying mass.
Objectives: To evaluate whether short-term follow-up mammography contributes to the detection of early cancer for patients with
microcalcification-only lesions that were diagnosed as benign stereotactic biopsy.
Patients and Methods: Two-hundred sixty-two microcalcification-only lesions in 259 women (mean age: 47.7 years) who were di-
agnosed as benign on stereotactic biopsy and been followed with mammography for at least 2 years were included. Serial mam-
mograms were reviewed from the initial pre-biopsy mammograms to the most recent examination. Mammographic findings were
designated as stable, decreased, or newly developed microcalcifications. Medical records of each patient were reviewed for clinical
information and pathology results of additional biopsy or surgical procedures.
Results: Of the 262 microcalcifications diagnosed as benign on stereotactic biopsy, 258 (98.5%) were finally diagnosed as benign, one
(0.4%) as high-risk lesion, and three (1.1%) as malignant. The three cancers were all diagnosed as ductal carcinoma in situ (DCIS) at 31,
36 and 6 months after initial biopsy. The DCIS diagnosed at 6 months post-biopsy had no mammographic changes, and was detected
on breast ultrasonography, while the remaining two cases had no detectable findings on the short-term follow-up mammography.
Conclusion: Short-term follow-up mammography did not contribute in detecting additional breast cancers, and may have a limited
role in patients diagnosed with benign-concordant microcalcifications on large-bore stereotactic biopsy.
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1. Background
Breast biopsy under imaging guidance is nowadays
widely accepted as an alternative to excisional biopsy be-
cause not only is it accurate, less invasive with minimal
scarring, and cost-effective (1, 2), it enables avoiding sec-
ond therapeutic surgeries for patients who are proven as
cancer on biopsy. According to the type of lesion detected,
the imaging modality that is considered to be most appro-
priate for guidance is used to maximize the diagnostic ac-
curacy of the biopsy procedures. For masses that are vi-
sualized on breast ultrasonography (US), US-guided core
needle biopsy is commonly considered, showing high di-
agnostic accuracy and sensitivity, 98.4% and 96.3%, respec-
tively (2, 3). As for lesions manifesting as microcalcifica-
tions on mammography without an accompanying mass,
stereotactic biopsy under mammography guidance is usu-
ally performed, since visualization and accurate targeting
of microcalcifications is difficult using US (4).
As for post-biopsy management, short-term follow-up
after biopsy is usually recommended for lesions with be-
nign results to avoid overlooking false-negative biopsy re-
sults. Imaging follow-up intervals vary among institutions,
ranging from 6 to 12 months (5-9), and currently there
are no strict post-biopsy guidelines for managing biopsy-
proven benign breast lesions. Recently, several reports sug-
gested that short-term imaging follow-up of 6 months is
unnecessary for asymptomatic benign-concordant breast
lesions, since similar cancer detection rates were observed
between patients with short-term follow-up and those
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with annual follow-up (6, 8-13). Yet, most of these stud-
ies evaluated the outcomes of either US-guided biopsies or
stereotactic biopsies of masses, and little has been evalu-
ated focusing on the outcome of microcalcification-only
lesions diagnosed as benign on mammography-guided
stereotactic biopsy.
2. Objectives
Based on this, the purpose of this study was to eval-
uate whether short-term follow-up mammography con-
tributes to the detection of early cancer for patients with
microcalcification-only lesions that were diagnosed as be-
nign stereotactic biopsy.
3. Patients and Methods
This retrospective study has been approved by our
institutional review board (IRB), and neither patient ap-
proval nor informed consent was required for review of im-
ages or medical records. Informed consent was obtained
from all patients prior to biopsy or surgery.
3.1. Patients
From January 2009 to December 2014, 643 breast
microcalcification-only lesions detected on mammogra-
phy in 622 women had undergone mammography-guided
stereotactic vacuum-assisted biopsy. Among them, 456
microcalcifications in 445 women were diagnosed as be-
nign, which was considered concordant to the imaging fea-
tures. Of these patients, 16 were excluded since they had
surgery after biopsy without follow-up images, 88 were ex-
cluded due to the lack of follow-up, and 90 were excluded
since they had been followed for less than 2 years after
biopsy. Finally, 262 microcalcifications in 259 women were
included in this study. The mean age of the 259 women
were 47.7 (range, 25 to 82) years. Mean follow-up interval
from biopsy to the most recent follow-up mammography
was 55.0 (range: 23.3 to 95.9) months.
3.2. Mammography Interpretation
Mammograms were performed with one of two ded-
icated digital mammography units (Senographe DS, GE
Medical Systems, Milwaukee, WI; Lorad Selenia, Hologic,
Danbury, CT). Standard mediolateral oblique (MLO) and
craniocaudal (CC) mammograms and magnification views
with 90º lateral and craniocaudal projections were ob-
tained for all patients. During the study period, one radi-
ologist among 20 radiologists dedicated to breast imaging
(four staff radiologists, 20 fellows, range of experience: 1 to
15 years) independently reviewed the mammograms and
categorized the microcalcifications. One radiologist with
8 years of experience in breast imaging (J.H.Y.) retrospec-
tively reviewed the mammograms and analyzed the imag-
ing features according to the 5th edition of the American
College of Radiology Breast Imaging Reporting and Data
System (ACR BI-RADS) (14).
3.3. Biopsy Procedures
Microcalcifications that were considered as suspicious
on mammography were targeted for biopsy. In cases of
multiple or extensive microcalcifications, the area show-
ing most suspicious morphology or the largest number of
microcalcifications were targeted.
Stereotactic biopsy was performed with the patient po-
sitioned in lateral decubitus position on the biopsy table
(Mammotome ST, Ethicon Endo-Surgery Inc., Cincinnati,
OH, USA). Biopsies were performed using either 11-gauge
or 8-gauge vacuum-assisted biopsy probes, needle size was
decided upon according to the extent of microcalcifica-
tions, breast thickness, and the preference of the perform-
ing radiologist. During the study period, three radiolo-
gists dedicated to breast imaging performed stereotactic
biopsy, each with 8 - 15 years of experience. Local anesthe-
sia was routinely applied using 1% lidocaine. Five or more
specimens were routinely retrieved during biopsy, and
specimen mammography was obtained to see if the tar-
geted microcalcifications had been sufficiently extracted
from the targeted area. Stereotactic biopsy of microcal-
cifications was considered adequate (1) if microcalcifica-
tions were detected on specimen mammography, and (2)
if the presence of microcalcifications was described on the
pathology reports. In cases that microcalcifications had
been completely extracted or the knowledge of the biopsy
site was critical in deciding upon surgical management,
post-biopsy clip (MammoMARK, Devicor Medical Products)
was placed immediately after biopsy procedures.
Routine mammography of the biopsied breast (MLO
and CC views) were obtained approximately 1 week after
biopsy at our institution to evaluate (1) post-biopsy com-
plications such as hematomas, (2) extent of the remnant
microcalcifications, (3) and the location of the post-biopsy
clip, if inserted.
3.4. Image-Histology Correlation
On the regular weekly conferences held in our breast-
imaging department, mammograms of the patients that
had undergone stereotactic biopsy for suspicious micro-
calcifications were reviewed, and decided upon concor-
dance between the imaging features of the microcalcifica-
tions and the pathologic diagnosis. Discordant biopsy re-
sults were defined as pathology results that were insuffi-
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cient to explain the microcalcifications seen on mammog-
raphy, and for these calcifications, additional diagnostic
surgery was recommended. Imaging follow-up with mam-
mography was recommended for benign-concordant mi-
crocalcifications, at 6, and 12 months after biopsy, then
yearly if stable.
3.5. Data and Statistical Analysis
Post-biopsy mammography performed at 4 - 9 month
interval was defined as short-term imaging follow-up (10).
Pathologic results from biopsy were classified into defini-
tive diagnosis, that is, specific pathologic entity that could
account for the lesion, including fibroadenoma, fibroade-
nomatous hyperplasia, tubular adenoma, hematoma or
inflammation, abscess, hamartoma, fat necrosis, granulo-
matous disease, lymph node, myofibroma, cyst contents,
pseudoangiomatous stromal hyperplasia (PASH), duct ec-
tasia. Benign, nonspecific results included fibrocystic
changes, adenosis, columnar cell change, fibrous mastopa-
thy, apocrine metaplasia, duct hyperplasia, and stromal fi-
brosis (9).
Chi-square test or Fisher’s exact test was used for com-
paring categorical variables. Independent t-test was used
to compare continuous variables. Statistical analysis was
done using PASW version 20 (IBM Corporation, Somers, NY,
USA). P values of less than 0.05 were considered to have sta-
tistical significance.
4. Results
Among the 262 microcalcifications in the 259 women
included in our study, 258 microcalcifications (98.5%) were
finally diagnosed as benign, one (0.4%) as high-risk lesion
(ADH), and three (1.1%) as malignant. Of the 259 women,
194 (74.9%) microcalcifications had short-term follow-up
mammography. Table 1 summarizes the demographics
and pathologic findings of the 262 microcalcifications in-
cluded in this study. The majority of benign-concordant
microcalcifications were assessed as BI-RADS category 4a
(n = 236, 90.1%), prior to biopsy. There were no significant
differences between the presences of short term follow-up
images according to BI-RADS final assessment category (P =
0.471). According to the pathologic diagnosis from biopsy,
20 (7.6%) cases had specific diagnosis and 242 (92.4%) had
nonspecific diagnosis, and the patients with short-term
follow-up mammography had significantly higher rates
of non-specific pathologic diagnosis, 94.8% to 85.3% (P =
0.022).
Among the 262 biopsy-proven benign microcalcifi-
cations, four (1.5%, 4 of 262) cases showed changes on
follow-up mammography, either increased number of pre-
existing microcalcifications on mammography or newly
developed lesions on breast ultrasonography (US) at the
same quadrant of the prior biopsy site (Table 2). One case
was diagnosed as 4-mm sized atypical ductal hyperpla-
sia on surgery performed on the newly developed micro-
calcifications detected on mammography 5 months after
stereotactic biopsy. One case that had been diagnosed as
malignancy 6 months after biopsy had a suspicious mass
detected on breast US located in the same quadrant as the
microcalcifications targeted for prior stereotactic biopsy.
No evident changes were seen on the follow-up mammog-
raphy performed after stereotactic biopsy (Figure 1). The
other two cases had newly developed microcalcifications
on follow-up mammography, which was considered sus-
picious requiring additional biopsy procedures (Figure 2).
All four cases that showed changes on follow-up breast
imaging after stereotactic biopsy had nonspecific patho-
logic diagnosis on initial stereotactic biopsy.
5. Discussion
In total, the malignancy rate for the benign-
concordant microcalcifications in this study was 1.1%
(3/262), which is within the < 2% range recommended for
ACR BI-RADS category 3 assessment (14). Our results are also
similar to the results of previous studies including biopsy-
proven benign lesions detected on US or mammography
(6, 11-13). In the prior studies (6, 11-13), the type of breast
lesion or the imaging modality used for guidance was not
limited to a specific type, showing low malignancy rates
for biopsy-proven benign lesions in general. In particular,
for cases representing as microcalcifications-only without
associated palpable lesions targeting for biopsy among
the microcalcifications, distribution of the lesions broadly
among the breast critically affects the diagnostic accuracy
of stereotactic biopsy. Based on this, we hypothesized
that microcalcification-only lesions diagnosed as benign
on stereotactic biopsy may have higher false-negative
results. Results of our study revealed a low malignancy
rate of the benign-concordant microcalcification-only
lesions consistent to prior studies, supporting that these
microcalcifications are at low risk for malignancy and
could be considered safe for follow-up.
Usually, imaging follow-up is recommended for
benign-concordant breast lesions to avoid any delayed
diagnosis of a possible false-negative biopsy (15), but at
present there are no standardized imaging follow-up
guidelines that specify a follow-up interval or duration
for lesions (8). Results of recent literature show that
short-term follow-up imaging does not contribute to
early detection of false-negative biopsies (6, 11-13, 16). As
for microcalcification-only lesions, since a considerable
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Table 1. Demographics of the 262 Microcalcifications Initially Diagnosed as Benign-Concordant on Stereotactic Biopsy According to Follow-Upa
Total 6-months follow-up (n = 194) Without 6-months follow-up (n = 68) P value
Age, y 47.7± 9.0 47.4± 8.7 48.7± 9.8 0.515
Pathologic diagnosis on ST-VABb 0.022
Specific 20 (7.6) 10 (5.2) 10 (14.7)
Non-specific 242 (92.4) 184 (94.8) 58 (85.3)
BI-RADS final assessment category 0.471
3 3 (1.1) 3 (1.5) 0 (0.0)
4a 236 (90.1) 173 (89.2) 63 (92.6)
4b 19 (7.3) 14 (7.2) 5 (7.4)
4c 4 (1.5) 4 (2.1) 0 (0.0)
Final pathologic diagnosis
Benign 258 (98.5) 191 (98.8) 67 (99.6)
Malignant 3 (1.1) 2 (0.8) 1 (0.4)
High risk lesion 1 (0.4) 1 (0.4) 0 (0.0)
Abbreviations: BI-RADS, breast imaging reporting and data system; SD, standard deviation; ST-VAB, stereotactic vacuum assisted biopsy
aValues are expressed as No. (%) or mean± SD.
bSpecific: including fibroadenoma, fibroadenomatous hyperplasia, and inflammation; non-specific: including fibrocystic change, adenosis, and columnar cell change
Table 2. Demographic and Imaging Features of the Four Cases Diagnosed as High-Risk or DCIS on Final Pathology

























































Grouped 4a 8 Fibrocystic
change with mi-
crocalcifications












Abbreviations: ADH, atypical ductal hyperplasia; DCIS, ductal carcinoma in situ; US, ultrasonography
amount of microcalcifications remain in the breast af-
ter stereotactic biopsy, imaging follow-up is critical not
to overlook hidden malignancies among the remnant
microcalcifications. In our study, the short-term follow-
up mammography did not contribute to detecting the
three ductal cancers in situ (DCIS) in our study, among
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Figure 1. A 63-year-old woman with suspicious microcalcifications in her left breast. A, Magnification mammography of the left breast shows multiple areas of grouped mi-
crocalcifications in the left breast, one of which was biopsied (circle), and diagnosed as fibrocystic changes with microcalcifications. B, Follow-up mammography performed
6 months after stereotactic biopsy revealed no remnant microcalcifications at the biopsy site (clip, dotted circle). C, Breast ultrasonography (US) shows a 5-mm sized hypoe-
choic mass with internal echogenic calcifications (arrow) in the left upper outer quadrant near the biopsy site. This mass was proven as ductal carcinoma in situ (DCIS) on
US-guided core biopsy and surgery.
which two of the three additional malignancies mani-
fested as changes on mammography performed 31 and
36 months after biopsy (Table 2). Our results support the
other studies in that short-term imaging follow-up after
benign stereotactic biopsy results for microcalcifications
do not contribute to early detection of cancers, but further
studies are anticipated to validate our results.
One of the three additional malignancies detected on
imaging follow-up had a newly developed suspicious mass
seen on breast US that was performed 6 months after
stereotactic biopsy. No changes were seen on the post-
biopsy mammography, especially at the prior biopsy site.
At our institution, breast US is performed with mammog-
raphy for patients scheduled for biopsy and during follow-
up examinations, to rule out the possibility of co-existing
US-detectable mass, since US-guided biopsy is easier and
more tolerable for the patient. Adding US to patients who
are being followed after stereotactic biopsy for benign mi-
crocalcifications may contribute to the early detection of
false-negative results, but whether US has an added role
in detecting additional cancers in patients with biopsy-
proven benign microcalcifications needs further investiga-
tion.
There are several limitations to this study. First, this
study was a retrospective study in which selection bias was
inevitable. Approximately, 56.7% of the benign-concordant
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Figure 2. A 50-year-old woman with suspicious microcalcifications in her right breast. A, Magnification mammography of the right breast shows multiple areas of grouped
amorphous microcalcifications in the right breast, one of which was biopsied (circle), diagnosed as columnar cell hyperplasia with microcalcifications. B, No significant
findings were seen at the biopsy site on the mammogram performed at 6 months after biopsy. C, Follow-up mammography performed 31 months after stereotactic biopsy
revealed newly developed fine pleomorphic/fine linear branching microcalcifications (arrows) located posteriorly to the prior biopsy site (dotted circle), which was proven
as ductal carcinoma in situ (DCIS) on both stereotactic biopsy and surgery.
microcalcifications were excluded from this study due to
the lack of imaging follow-up for more than 2 years. Sec-
ond, not all patients had undergone short-term imaging
follow-up, in which our results may have its limitations in
representing the true effectiveness of short-term imaging
follow-up. Third, one radiologist retrospectively reviewed
the mammography images for microcalcifications. Ob-
server variability for microcalcification interpretation was
not considered in this study.
In conclusion, the malignancy rate for benign concor-
dant microcalcifications diagnosed with large bore stereo-
tactic biopsy was 1.1%. Short-term follow-up mammogra-
phy did not contribute in detecting additional breast can-
cers, and may have a limited role in patients diagnosed
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with benign-concordant microcalcifications on large-bore
stereotactic biopsy.
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